Taken together, these data suggest that FGF2, through both DNMT1/ERK-dependent and -independent pathways, potently antagonizes the expression of EC CAMs and chemokines that are important for CTL homing and entry into tumors or tumor-draining lymph nodes (Fig. 7h). This evidence concerns the gene FGF2 and neoplasm.